Subscribe
pfizer_istock-458618835_no_limit_pictures--2
no_limit_pictures / iStockphoto.com
31 July 2018Americas

Pfizer expects $1.9bn loss due to patent expirations

US-based pharmaceutical company  Pfizer today reported an increase in year-on-year revenue for the second quarter but projected nearly a $2 billion loss in 2018 due to patent expirations.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Sun Pharma takes Pfizer to court over Lyrica
8 April 2019   India-based drugmaker Sun Pharma has accused Pfizer of infringing a patent with a new extended-release formulation of Lyrica.
Big Pharma
Pfizer revenues to slow as drugs lose exclusivity
31 January 2019   American pharmaceutical company Pfizer warned investors of little revenue growth to come in 2019, owing partly to expiring exclusivity rights on drugs including Viagra and the seizure medicine Lyrica.
Big Pharma
Pfizer secures six-month Lyrica extension in US
29 November 2018   The US Food and Drug Administration has granted Pfizer paediatric exclusivity for Lyrica, extending the period of US market exclusivity for the drug by six months.


Editor's picks

‘We created law’: G1/24 and the creation of the ‘diamond standard’
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

Editor's picks

Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Americas
Sun Pharma takes Pfizer to court over Lyrica
8 April 2019   India-based drugmaker Sun Pharma has accused Pfizer of infringing a patent with a new extended-release formulation of Lyrica.
Big Pharma
Pfizer revenues to slow as drugs lose exclusivity
31 January 2019   American pharmaceutical company Pfizer warned investors of little revenue growth to come in 2019, owing partly to expiring exclusivity rights on drugs including Viagra and the seizure medicine Lyrica.
Big Pharma
Pfizer secures six-month Lyrica extension in US
29 November 2018   The US Food and Drug Administration has granted Pfizer paediatric exclusivity for Lyrica, extending the period of US market exclusivity for the drug by six months.

More on this story

Americas
Sun Pharma takes Pfizer to court over Lyrica
8 April 2019   India-based drugmaker Sun Pharma has accused Pfizer of infringing a patent with a new extended-release formulation of Lyrica.
Big Pharma
Pfizer revenues to slow as drugs lose exclusivity
31 January 2019   American pharmaceutical company Pfizer warned investors of little revenue growth to come in 2019, owing partly to expiring exclusivity rights on drugs including Viagra and the seizure medicine Lyrica.
Big Pharma
Pfizer secures six-month Lyrica extension in US
29 November 2018   The US Food and Drug Administration has granted Pfizer paediatric exclusivity for Lyrica, extending the period of US market exclusivity for the drug by six months.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?